Objective: To analyze the hepatitis B virus serological markers (HBVM) and abnormal rates of liver function indexes among primary liver cancer (PLC) patients with different HBVM profiles, so as to provide a reference for risk stratification and optimization of diagnosis and treatment strategies for PLC patients. Methods: Patients diagnosed with PLC at Qidong People's Hospital between January 2017 and June 2024 were selected for this study. Basic information such as gender and age was collected through the hospital information management system. Venous blood samples were drawn to test for HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc, as well as ten liver function indexes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), cholinesterase (CHE), and adenosine deaminase (ADA). Compare the abnormal rates of liver function indexes among the six HBVM profiles: "big three yang" (HBsAg+, HBeAg+, anti-HBc+), "small three yang" (HBsAg+, anti-HBe+, anti-HBc+), triple antibody positive (anti-HBs+, anti-HBe+, anti-HBc+), s/c antibody positive (anti-HBs+, anti-HBc+), e/c antibody positive (anti-HBe+, anti-HBc+), and all negative. Results: A total of 1 434 patients with PLC were enrolled in this study. Among them, 1 043 (72.73%) were males and 391 (27.27%) were females. The median age was 64.00 (interquartile range, 16.00) years. The positive rates for HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc were 51.95%, 29.43%, 10.81%, 60.32%, and 88.42%, respectively. The "big three yang", "small three yang", triple-antibody positive, s/c antibody positive, e/c antibody positive, and all-negative profiles accounted for 85 (5.93%), 491 (34.24%), 170 (11.85%), 148 (10.32%), 100 (6.97%), and 121 (8.44%) cases, respectively. The abnormal rates of ALT among PLC patients with six HBVM profiles were 26.19%, 28.33%, 13.94%, 22.60%, 20.41%, and 14.91%, respectively. The abnormal rates of AST were 33.33%, 36.17%, 23.03%, 24.66%, 22.45%, and 18.42%, respectively. The abnormal rates of LDH were 62.16%, 68.22%, 53.73%, 61.19%, 60.00%, and 68.42%, respectively. The abnormal rates of CHE were 0%, 1.81%, 0%, 2.11%, 2.22%, and 3.88%, respectively. The abnormal rates of ADA were 59.09%, 57.27%, 24.27%, 33.33%, 45.00%, and 37.04%, respectively. These differences were statistically significant (all P<0.05). Conclusions In this study, the HBVM profiles were mainly characterized by "small triple positive" among PLC patients. The significant differences in liver function indexes abnormal rates among PLC patients with six HBVM profiles could reflect the liver injury status.

Objective To detect the expression level of hsa_circ_0082002 in serum of patients with primary hepatocellular carcinoma(HCC)and explore its auxiliary diagnostic value.Methods A total of 70 HCC pa-tients treated in this hospital from January 2020 to December 2022 were selected as the HCC group,55 pa-tients with liver cirrhosis(LC)were selected as the LC group,55 patients with chronic hepatitis B(CHB)were selected as the CHB group,and 50 healthy people were selected as the control group.The relative expres-sion level of hsa_circ_0082002 in serum of each group was detected by real-time fluorescent quantitative PCR,and the level of serum alpha-fetoprotein(AFP)was detected by electrochemiluminescence.The receiver oper-ating characteristic(ROC)curve was used to evaluate the differential diagnostic efficacy of hsa_circ_0082002 and AFP for HCC.Results The relative expression levels of serum hsa_circ_0082002 in HCC group,LC group,CHB group and control group were 2.750(1.925,4.393),2.199(1.416,2.850),1.591(0.925,2.107)and 1.035(0.666,1.680),respectively.The relative expression level of serum hsa_circ_0082002 in the HCC group was higher than those in the LC group,CHB group and HC group,and the differences were statistically signifi-cant(all P＜0.05).The results of ROC curve showed that the area under the curve(AUC)of hsa_circ_0082002 and AFP in the differential diagnosis of HCC were 0.813 and 0.779,respectively.The AUC of combined detection of hsa_circ_0082002 and AFP was 0.871,with a sensitivity of 75.71％and specificity of 83.13％.Conclusion Serum hsa_circ_0082002 may be a biomarker for the diagnosis of HCC.